PSC News

Mirum Pharmaceuticals recently announced positive results from the Phase 2b VISTAS clinical trial evaluating volixibat, an investigational treatment for itch (pruritus) in people living with primary sclerosing cholangitis (PSC). What Is Volixibat? Volixibat is a medication designed to reduce the amount of bile acids circulating in the body. In PSC, bile acids can build up … Read more

Significant and encouraging clinical trial news in the field of primary sclerosing cholangitis (PSC) drug development. The trial sponsor, Ipsen and developer, GENFIT, announced on Feb. 12, 2026, that elafibranor has progressed to a Phase 3 clinical trial for PSC, known as the ELASCOPE study. Advancing to a Phase 3 trial represents an important milestone … Read more

In November 2025, thousands of global experts gathered for The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), a professional association for doctors, scientists, and healthcare providers focused on preventing, curing, and treating liver diseases. The Liver Meeting® is recognized as the largest gathering of hepatologists and liver … Read more

In December 2025, the European Rare Diseases Research Alliance (ERDERA) announced that a collaborative transnational PSC research project was funded. This project, named ASCENT-PSC, is led by a Canadian Toronto-based team. ERDERA’s investment in rare disease research includes an expectation of genuine patient-partnership. The research team is led by Sonya MacParland at University Health Network … Read more

The Loon Duct e-newsletter helps the PSC Community in Canada stay up to date on upcoming events, research, and other PSC news. Emailed quarterly, the newsletter also highlights people’s stories about their experiences living with PSC. Most Recent Issue: December 2025 In the December 2025 issue of The Loon Duct, read the 2025 Year in Review, … Read more

Fantastic news was released today about the Developing Medicines through Open Science program from Canadian organization Conscience which is supporting open science and nonprofit drug development. In honour of the upcoming Rare Disease Day (Feb 28, 2025), today’s grant announcement includes PSC! PSC Partners and PSC Partners Canada are proud to be a part of … Read more